This is our first report on biopharma player, Alnylam Pharmaceuticals that is focused on developing novel therapeutics based on the ribonucleic acid interference. The company has made great progress to bring its commercial RNAi Therapeutics to patients all over the world and advanced its clinical pipelines over various potential transformative programs. Alnylam Pharmaceuticals recently announced the approval of the RNAi therapeutic, Amvuttra(vutrisiran) administered through subcutaneous injection quarterly. Amvuttra will treat hATTR amyloidosis (hereditary transthyretin-mediated)’s polyneuropathy in adults. Alnylam Pharmaceuticals also reported top-line positive results from the study of Phase 2 of Investigational Cemdisiran. Onpattro, Oxlumo, and Givlaari gave a positive performance in the recent results and the company has more than 1875 patients in commercial treatments. The patient growth rate quarter-on-quarter has steady for the company mainly because of geographical expansion. The management continues to see growth in the U.S on various fronts, which includes a 12% growth in demand with respect to new prescribers. We initiate coverage on the stock of Alnylam with a ‘Hold’ rating.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $99 annual subscription!